ChemoMetec (CHEMM) Q3 2025 earnings summary

Executive summary

• Q3 2024/25 revenue rose 26% year-over-year to DKK 124.2 million, driven by strong NC platform sales and increased customer activity in clinical trials and approved therapies.

• EBITDA increased 47% to DKK 63.4 million, with margin improving to 51% from 44% in Q3 2023/24.

• Product launches, notably XcytoMatic and NC-203, are progressing as planned, with customer validations tripling year-over-year.

Financial highlights

• Q3 revenue: DKK 124.2 million (+26% YoY); 9M revenue: DKK 375.7 million (+26% YoY).

• Q3 EBITDA: DKK 63.4 million (+47% YoY); 9M EBITDA: DKK 198.6 million (+46% YoY).

• Q3 EBITDA margin: 51% (up from 44%); 9M EBITDA margin: 53% (up from 46%).

• Sales of instruments grew 23% in Q3 and 37% in 9M; consumables up 18% in Q3 and 18% in 9M; services up 47% in Q3 and 30% in 9M.

Outlook and guidance

• Full-year revenue guidance maintained at DKK 470-490 million; EBITDA guidance at DKK 250-260 million.

• Guidance unchanged despite geopolitical and macroeconomic uncertainties, including USD weakness and new US tariffs.